时间:2021-02-04 17:11:33来源: 德国新闻网
Beijing-based Sinovac Life Sciences Co., Ltd. on Wednesday filed an application with Chinese authorities for conditional marketing authorization of its anti-COVID-19 vaccine CoronaVac.
The application has been received by the National Medical Products Administration (NMPA), according to Sinovac Biotech Ltd., which has a majority stake in the vaccine producer.
The inactivated vaccine CoronaVac has made progress in phase three clinical trials overseas, showing a good level of safety after inoculation, according to a company statement.
Fourteen days after the inoculation of two doses of CoronaVac, the effectiveness of the vaccine in protecting against diseases caused by COVID-19 has met the relevant technical standards laid out by the World Health Organization and the requirements of the NMPA, the statement said.
Chinese eVTOL aircraft completes test flight in Shanghai
2024-05-15Nation's self-developed satellite to launch service in HKSAR
2024-05-10China's third aircraft carrier begins its maiden sea trial
2024-05-04People in Tangshan welcome destroyer named after the city
2024-04-26Air China prepares to resume four more international routes
2024-04-23PLA lawfully responds to U.S. aircraft flying through Taiwan Strait
2024-04-18China issues guideline to raise annual food yield
2024-04-10China's largest land port handles over 5 mln metric tons of imports and exports in Q1
2024-04-04